An observational study in Acute Myocardial Infarction (AMI) and Percutaneous Coronary Intervention (PCI), sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Shanghai Zhongshan Hospital · Observational
Among 194 studies in Myocardial Infarction with a site in China — 62 open to participants now, 71 under way, 7 of them phase 3. Myocardial Infarction · China.
Among the 194 studies in Myocardial Infarction with a site in China, this one is the 17th largest by planned enrollment of the 88 observational ones that give a count, is one of 19 that started in 2026, is one of 88 observational ones, reaches primary completion later than 63 of the 70 other live ones, and was the 193rd registered.
2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.
Browse Myocardial Infarction studies →62 of the 194 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:
Beijing Hospital · Sites in China
Shanghai Zhongshan Hospital · Sites in China
Beijing Anzhen Hospital · Sites in China
Shanghai Zhongshan Hospital · Sites in China
Nanjing First Hospital, Nanjing Medical University · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 255 Myocardial Infarction studies recruiting now, 172 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 16 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 21 · Phase 4 32
First in 1999; this study’s year is marked. 19 started in 2026.
This study's planned enrollment of 8,000 is above the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 364 across the 106 interventional studies, 1,000 across the 88 observational. Of the 74 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 194 have an industry lead sponsor. The 10 most frequent:
Shanghai Zhongshan Hospital is the lead sponsor of 652 studies on the registry; 291 are open to participants now.
Shanghai Zhongshan Hospital has 9 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
21 of the studies in Myocardial Infarction with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07381803Phase 3Second Affiliated Hospital, Zhejiang University, School of MedicineThe Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction | 2026-12 |
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT07320625Phase 3Shanghai Zhongshan HospitalEfficacy of Montelukast on STEMl Patients | 2027-02-01 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05891145Yangzhou UniversityRemimazolam for Postoperative Atrial Fibrillation | 2026-12 |
Among the 194 studies in Myocardial Infarction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center, ambispective cohort study will use real-world data from Zhongshan Hospital, Fudan University. About 8,000 patients aged 18 years or older with acute myocardial infarction (AMI) who underwent primary percutaneous coronary intervention (PCI) from 2009 to 2028 will be included. Patients will be grouped into four periods: 2009-2013, 2014-2018, 2019-2023, and 2024-2028. The study aims to describe 20-year trends in in-hospital events and major adverse cardiovascular and cerebrovascular events (MACCE) within 2 years after PCI and to identify independent risk factors. The primary outcome is MACCE within 2 years, defined as a composite of all-cause death, recurrent myocardial infarction, ischemia-driven repeat revascularization, and non-fatal ischemic stroke. Key secondary outcomes include in-hospital all-cause death, impaired myocardial perfusion, malignant arrhythmia, acute heart failure, recurrent myocardial infarction, non-fatal ischemic stroke, and bleeding events. Data will come from electronic medical records and the cardiac catheterization database.
Background: Acute myocardial infarction (AMI) is a leading cause of cardiovascular death in China. Primary PCI improves outcomes, but patients remain at risk of in-hospital events and long-term major adverse cardiovascular and cerebrovascular events (MACCE). Long-term real-world evidence from China is limited.
Design: This single-center, ambispective cohort study will include about 8,000 AMI patients aged 18 years or older treated with primary PCI at Zhongshan Hospital, Fudan University, from 2009 to 2028. Patients will be divided into four periods: 2009-2013, 2014-2018, 2019-2023, and 2024-2028. Follow-up will be 2 years after PCI or until an endpoint event, death, or loss to follow-up.
Objectives: To describe the incidence and 20-year trends of in-hospital events and 2-year MACCE, and to identify independent risk factors.
Outcomes: The primary outcome is 2-year MACCE, defined as a composite of all-cause death, recurrent myocardial infarction, ischemia-driven repeat revascularization, and non-fatal ischemic stroke. The key secondary outcome is in-hospital all-cause death. Other secondary outcomes include impaired myocardial perfusion, malignant arrhythmia, acute heart failure, recurrent myocardial infarction, non-fatal ischemic stroke, and bleeding events.
Data and Analysis: Data will be obtained from electronic medical records and the cardiac catheterization database. Retrospective data will be collected for 2009-2026, with prospective enrollment for 2027-2028. Descriptive analysis, Kaplan-Meier method, log-rank test, Cox proportional hazards models, and logistic regression will be used. Subgroup and sensitivity analyses will be performed.
Ethics: Ethical approval will be obtained from the Ethics Committee of Zhongshan Hospital, Fudan University. Written informed consent will be obtained from prospective patients; verbal consent or a waiver will be requested for retrospective patients. No study-specific interventions are involved in this observational study.
This study is an ambispective, registry-based cohort study that includes patients diagnosed with acute myocardial infarction who underwent primary percutaneous coronary intervention (PCI) at Zhongshan Hospital, Fudan University, from January 1, 2009, to December 31, 2028.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acute myocardial infarction patients undergoing primary PCI
Other: Collection of baseline characteristics
Collection of baseline clinical characteristics, procedural details, laboratory results, and medication records
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Composite of all-cause death, recurrent myocardial infarction, ischemia-driven repeat revascularization, and non-fatal ischemic stroke. The first occurrence of any component will be used for time-to-event analysis.
Time frame: Within 2 years after PCI
In-hospital all-cause death
Death from any cause during hospitalization.
Time frame: Perioperative/Periprocedural
In-hospital impaired myocardial perfusion
Post-PCI TIMI flow grade \<3 in the infarct-related artery.
Time frame: At the end of the PCI procedure
In-hospital malignant arrhythmia
New-onset ventricular tachycardia, ventricular fibrillation, or other malignant arrhythmias requiring drug therapy, electrical cardioversion/defibrillation, or temporary pacing during hospitalization.
Time frame: Perioperative/Periprocedural
In-hospital acute heart failure
New-onset or worsening acute heart failure requiring intravenous diuretics, vasoactive drugs, or mechanical support (e.g., IABP, ECMO).
Time frame: Perioperative/Periprocedural
In-hospital recurrent myocardial infarction
Recurrent myocardial infarction during hospitalization.
Time frame: Perioperative/Periprocedural
In-hospital non-fatal ischemic stroke
Non-fatal ischemic stroke during hospitalization.
Time frame: Perioperative/Periprocedural
All-cause death within 2 years after PCI
Death from any cause within 2 years after PCI.
Time frame: Within 2 years after PCI
Cardiovascular death within 2 years after PCI
Death from cardiovascular causes within 2 years after PCI. Cardiovascular death includes death due to myocardial infarction, heart failure, arrhythmia, stroke, or other cardiovascular causes.
Time frame: Within 2 years after PCI
Recurrent myocardial infarction within 2 years after PCI
Recurrent myocardial infarction within 2 years after PCI.
Time frame: Within 2 years after PCI
Ischemia-driven repeat revascularization within 2 years after PCI
Repeat PCI or CABG driven by ischemia within 2 years after the index PCI.
Time frame: Within 2 years after PCI
Non-fatal ischemic stroke within 2 years after PCI
Non-fatal ischemic stroke within 2 years after PCI.
Time frame: Within 2 years after PCI
Bleeding events
Bleeding events defined by the Bleeding Academic Research Consortium (BARC) within 2 years after PCI.
Time frame: Within 2 years after PCI
Cardiac function status during long-term follow-up
To document changes in left ventricular ejection fraction (LVEF) during long-term follow-up. A normal LVEF is defined as \>53%, while an LVEF \<50% indicates impaired left ventricular systolic function.
Time frame: Up to 2 years after PCI
Malignancy as a Negative Control Outcome
Incident malignancy or malignancy-related death within 2 years after PCI, used as a negative control outcome to assess potential detection bias, surveillance bias, or residual confounding.
Time frame: Within 2 years after PCI
Plan to share: No — The research involves some confidential content
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2030, 51 months after the start.
Of 296 non-industry observational studies under Myocardial Infarction, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 140. This study's planned 51 months is close to that.
Counting every sponsor, half of 333 studies reached it within 48 months; a quarter within 17 and three quarters within 114.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Sep 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.